AU2003287955B2 - Methods to predict cholesterol elevations during immunosuppressant therapy - Google Patents

Methods to predict cholesterol elevations during immunosuppressant therapy Download PDF

Info

Publication number
AU2003287955B2
AU2003287955B2 AU2003287955A AU2003287955A AU2003287955B2 AU 2003287955 B2 AU2003287955 B2 AU 2003287955B2 AU 2003287955 A AU2003287955 A AU 2003287955A AU 2003287955 A AU2003287955 A AU 2003287955A AU 2003287955 B2 AU2003287955 B2 AU 2003287955B2
Authority
AU
Australia
Prior art keywords
patient
gene
haplotype
cholesterol
medication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003287955A
Other languages
English (en)
Other versions
AU2003287955A1 (en
AU2003287955B9 (en
Inventor
Sridhar Kudaravalli
Mihael Hristos Polymeropoulos
Rosarelis Torres
Curt Douglas Wolfgang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32043422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2003287955(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of AU2003287955A1 publication Critical patent/AU2003287955A1/en
Publication of AU2003287955B9 publication Critical patent/AU2003287955B9/en
Publication of AU2003287955B2 publication Critical patent/AU2003287955B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2003287955A 2002-09-30 2003-09-29 Methods to predict cholesterol elevations during immunosuppressant therapy Ceased AU2003287955B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41512302P 2002-09-30 2002-09-30
US60/415,123 2002-09-30
PCT/EP2003/010798 WO2004029618A2 (en) 2002-09-30 2003-09-29 Methods to predict cholesterol elevations during immunosuppressant therapy

Publications (3)

Publication Number Publication Date
AU2003287955A1 AU2003287955A1 (en) 2004-04-19
AU2003287955B9 AU2003287955B9 (en) 2004-04-19
AU2003287955B2 true AU2003287955B2 (en) 2007-06-21

Family

ID=32043422

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003287955A Ceased AU2003287955B2 (en) 2002-09-30 2003-09-29 Methods to predict cholesterol elevations during immunosuppressant therapy

Country Status (13)

Country Link
US (2) US7732134B2 (enExample)
EP (1) EP1549770B1 (enExample)
JP (1) JP4575775B2 (enExample)
CN (1) CN100453650C (enExample)
AT (1) ATE389034T1 (enExample)
AU (1) AU2003287955B2 (enExample)
BR (1) BR0314552A (enExample)
CA (1) CA2500979A1 (enExample)
DE (1) DE60319719T2 (enExample)
ES (1) ES2302959T3 (enExample)
IL (1) IL167639A (enExample)
PT (1) PT1549770E (enExample)
WO (1) WO2004029618A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0611021A2 (pt) * 2005-05-31 2010-08-10 Novartis Ag combinação de inibidores de hmg-coa redutase e inibidores de mtor
DK2496720T3 (da) 2009-11-06 2020-09-28 Univ Leland Stanford Junior Ikke-invasiv diagnose af transplantatafstødning i organ-transplanterede patienter
KR101924162B1 (ko) * 2010-03-15 2018-11-30 버지니아 커먼웰스 유니버시티 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손
US20130203769A1 (en) * 2012-02-08 2013-08-08 University Of Cincinnati Targeting Metabolic Adaptive Responses to Chemotherapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268142B1 (en) * 1997-05-29 2001-07-31 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686246A (en) 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
US5698399A (en) * 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis
US6524795B1 (en) * 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
US6210877B1 (en) * 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
KR101019131B1 (ko) * 2001-11-19 2011-03-07 인터레우킨 제네틱스, 인코포레이티드 염증성 질환 및 감염성 질환에 대한 감수성 및 전사에영향을 미치는 인터루킨-1 좌의 기능적 다형성

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268142B1 (en) * 1997-05-29 2001-07-31 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype

Also Published As

Publication number Publication date
WO2004029618A2 (en) 2004-04-08
JP2006500930A (ja) 2006-01-12
CA2500979A1 (en) 2004-04-08
EP1549770B1 (en) 2008-03-12
CN1685062A (zh) 2005-10-19
DE60319719D1 (de) 2008-04-24
EP1549770A2 (en) 2005-07-06
US20060246439A1 (en) 2006-11-02
AU2003287955A1 (en) 2004-04-19
US7732134B2 (en) 2010-06-08
ATE389034T1 (de) 2008-03-15
IL167639A (en) 2011-10-31
HK1084445A1 (zh) 2006-07-28
PT1549770E (pt) 2008-06-24
JP4575775B2 (ja) 2010-11-04
US20100184798A1 (en) 2010-07-22
BR0314552A (pt) 2005-08-09
CN100453650C (zh) 2009-01-21
DE60319719T2 (de) 2009-03-12
WO2004029618A3 (en) 2004-06-17
ES2302959T3 (es) 2008-08-01
AU2003287955B9 (en) 2004-04-19

Similar Documents

Publication Publication Date Title
AU2004283235B2 (en) Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory disease
JP2012507297A (ja) Ｅｒｂｂ４遺伝子の多型に基づく精神病及び統合失調症の治療法
US20080166723A1 (en) CDK5 genetic markers associated with galantamine response
US20100184798A1 (en) Methods to Predict Cholesterol Elevations during Immunosuppressant Therapy
CA2555367A1 (en) Apoe genetic markers associated with age of onset of alzheimer's disease
AU2005250142B2 (en) Biomarkers for the prediction of responsiveness to clozapine treatment
US20050250118A1 (en) EPHX2 Genetic markers associated with galantamine
CA2542629A1 (en) Ntrk1 genetic markers associated with age of onset of alzheimer's disease
EP1673472B1 (en) Use of genetic polymorphisms to predict drug-induced hepatotoxicity
US20050260613A1 (en) LRPAP1 genetic markers associated with galantamine
US20050048543A1 (en) CHRNA2 genetic markers associated with galantamine response
US20050255492A1 (en) CHRNA9 genetic markers associated with progression of Alzheimer's disease
HK1084445B (en) Methods to predict cholesterol elevations during immunosuppressant therapy
WO2004003167A2 (en) Gucy1b2 genetic markers for ldl cholesterol response to statin therapy
EP1516066A1 (en) Methods for the detection of polymorphisms in the human oatpf gene
WO2003091698A2 (en) Cetp genetic markers for statin-specific changes in hdl cholesterol

Legal Events

Date Code Title Description
SREP Specification republished
MK14 Patent ceased section 143(a) (annual fees not paid) or expired